Holen Sie sich die Stockscreener-App
12.14
5.50%
0.688
Schlusskurs vom Vortag:
$11.45
Offen:
$11.48
24-Stunden-Volumen:
638.65K
Relative Volume:
0.97
Marktkapitalisierung:
$579.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-59.85M
KGV:
-13.70
EPS:
-0.8857
Netto-Cashflow:
$-54.54M
1W Leistung:
+37.59%
1M Leistung:
+79.23%
6M Leistung:
+519.49%
1J Leistung:
+906.67%
1-Tages-Spanne:
$11.31
$12.20
1-Wochen-Bereich:
$7.91
$12.15
52-Wochen-Spanne:
$1.13
$12.15
Climb Bio Inc Stock (CLYM) Company Profile
Firmenname
Climb Bio Inc
Sektor
Branche
Telefon
1-866-857-2596
Adresse
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
12.14 | 546.95M | 0 | -59.85M | -54.54M | -0.8857 |
VRTX
Vertex Pharmaceuticals Inc
|
425.19 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.55 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.76 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.29 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.86 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Mizuho | Outperform |
| 2026-03-24 | Eingeleitet | B. Riley Securities | Buy |
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-03-05 | Eingeleitet | Wedbush | Outperform |
| 2026-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | William Blair | Outperform |
| 2025-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-08-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-06-06 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE - Yahoo Finance
Climb Bio Secures 110 Million Dollars Through Private Stock Placement - HarianBasis.co
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing - Insider Monkey
Climb Bio reports B-cell depletion data for budoprutug trial - Investing.com UK
Drug shot matched IV B-cell depletion in Climb Bio study; June data next - Stock Titan
Climb Bio Highlights Budoprutug Progress at R&D Spotlight - TipRanks
Climb Bio : Budoprutug and the CD19 Opportunity - marketscreener.com
Climb Bio shares positive topline SC budoprutug data, ITP readout June, pMN & SLE readouts Q4 2026 - TradingView
Climb Bio (CLYM) outlines budoprutug CD19 data, 2026 trial readouts and cash runway - Stock Titan
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting - GlobeNewswire
Chardan initiates Climb Bio stock with buy on autoimmune pipeline By Investing.com - Investing.com India
5 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Analysts Raise Price Targets for Climb Bio Following Clinical Updates - HarianBasis.co
Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026 - Insider Monkey
CLYM Stock Price, Quote & Chart | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
RA Capital funds receive Climb Bio (CLYM) pre-funded warrants in new grant - Stock Titan
RA Capital lifts Climb Bio (CLYM) stake with $20M PIPE warrants - Stock Titan
Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney Disease - Insider Monkey
5 Best Performing Small Cap Stocks So Far in 2026 - Insider Monkey
10 Tiny Stocks That Are On Fire Right Now - Insider Monkey
Climb Bio raises $110 million in private placement - Investing.com UK
Climb Bio raises $110 million in private placement By Investing.com - Investing.com Australia
Budoprutug potential in CD19 antibody therapy spotlighted by Climb Bio, Inc. - Traders Union
Climb Bio raises $110M in private placement; shares up - MSN
Climb Bio, Inc. announced that it expects to receive $110.076289 million in funding from a group of investors - marketscreener.com
Climb Bio Raises $110 Million in Private Placement - TipRanks
Climb Bio (CLYM) secures $110M private placement with institutional investors - Stock Titan
Climb Bio, Inc. Announces $110.0 Million Private Placement - markets.businessinsider.com
Climb Bio, Inc. Announces $110 Million Private Placement of Common Stock and Pre-Funded Warrants - Quiver Quantitative
CLIMB BIO INCPRIVATE PLACEMENT EXPECTED TO CLOSE ON OR ABOUT APRIL 29, 2026 - Moomoo
Institutional investors commit $110M in Climb Bio share sale - Stock Titan
Climb Bio, Inc. joins The Future of Clinical Trial Design in IgA nephropathy - Traders Union
Executive pay and governance moves at Climb Bio (NASDAQ: CLYM) - Stock Titan
Mizuho initiates coverage of Climb Bio (CLYM) with outperform recommendation - MSN
CLYM (Climb Bio Inc.) rises 3.85 percent even as fourth quarter 2025 per share earnings miss analyst estimates.Hedge Fund Inspired Picks - UBND thành phố Hải Phòng
BLTE (Belite Bio Inc American Depositary Shares) posts wider Q4 2025 loss than estimates, shares climb amid optimistic investor sentiment.Cost Structure - Xã Thanh Hà
Climb Bio, Inc. $CLYM Shares Sold by JPMorgan Chase & Co. - MarketBeat
Climb Bio, Inc. (NASDAQ:CLYM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Oppenheimer Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $18 - Moomoo
Climb Bio Sees Upgraded Outlook on Strong IgAN Drug Development Pipeline, Oppenheimer Says - marketscreener.com
Oppenheimer Raises Climb Bio (NASDAQ:CLYM) Price Target to $18.00 - MarketBeat
Oppenheimer Adjusts Price Target on Climb Bio to $18 From $10, Maintains Outperform Rating - marketscreener.com
Oppenheimer raises Climb Bio stock price target on clinical data By Investing.com - Investing.com Canada
FDA Grants Fast Track Designation to Climb Bio Kidney Drug - HarianBasis.co
FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock? - Insider Monkey
8 Must-Buy Small Cap Stocks to Buy - Insider Monkey
Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway (CLYM) - Seeking Alpha
Climb Bio, Inc. backs scientific collaboration on innovative trial design in nephrology - Traders Union
Climb Bio (NASDAQ:CLYM) Upgraded to "Strong-Buy" at Mizuho - MarketBeat
Finanzdaten der Climb Bio Inc-Aktie (CLYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Climb Bio Inc-Aktie (CLYM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thomas Stephen Basil | Director |
Feb 26 '26 |
Sale |
7.01 |
16,313 |
114,289 |
154,657 |
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):